| Source: |
| Type: |
| SHP1 is a non-receptor protein tyrosine phosphatase primarily encoded by the gene PTPN6. Immune Checkpoint Brake, Tumor Suppressor Signaling, and Immune Evasion – In blood cancers such as leukemia and lymphoma, altered SHP1 expression (often downregulation) is frequently observed. – Downregulation or loss of SHP1 is often associated with more aggressive disease phenotypes and poorer prognosis. Direction of Regulation in Cancer Two distinct, context-specific directions: A. Tumor Cells (especially hematologic malignancies): DOWNREGULATED -Frequently silenced epigenetically (promoter methylation) -Rarely mutated; loss is regulatory -Results in unchecked growth and survival signaling B. Immune Cells within the Tumor Microenvironment: FUNCTIONALLY UPREGULATED -Actively recruited by inhibitory receptors -Suppresses T-cell, NK-cell, and myeloid anti-tumor responses -Promotes immune evasion This duality is critical to interpret SHP1 correctly. When SHP1 is lost in tumor cells: -JAK–STAT signaling becomes hyperactive -Growth and survival pathways escape negative feedback -Cells gain a proliferative and survival advantage |
| 2773- | Bos, | Targeted inhibition of tumor proliferation, survival, and metastasis by pentacyclic triterpenoids: Potential role in prevention and therapy of cancer |
| - | Review, | Var, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:1331 State#:% Dir#:1
wNotes=0 sortOrder:rid,rpid